What is Nutriband's market cap?

Nutriband (NTRB) has a market capitalization of $35.9M and trades on NASDAQ.

Who are Nutriband's competitors?

Nutriband's key competitors include Johnson & Johnson, Mylan, Aquestive Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Nutriband partner with?

Nutriband's notable partners include Kindeva Drug Delivery, Brand Institute, Inc, Health Advances, and others.

What subsidiaries does Nutriband have?

Nutriband's subsidiaries include 4P Therapeutics, Pocono Pharmaceuticals Inc., Active Intelligence LLC, and others.

Where is Nutriband headquartered?

Nutriband is headquartered in United States of America and employs approximately 3 people. It has been publicly traded since 2017.

Nutriband

NTRB

Nutriband Inc. is a biotechnology company focused on developing a portfolio of transdermal pharmaceutical products, primarily utilizing its proprietary AVERSA abuse-deterrent technology.

Market cap

$35.92M-54.7%

Table of contents

Earnings

Q2 2026 report

June 11, 2026

Revenue$433.4K EPS-$0.10

Read the full report

Next report

Sep 30, 2026 (in 2 months)

Competitors

By market cap

Johnson & Johnson$642.79B+58.8%

Viatris$20.8B+92.8%

AMP

Amphastar Pharmaceuticals$888.5M-13.0%

Aquestive Therapeutics, Inc.$471.8M+20.9%

Nutriband$35.9M-57.2%

Dare Bioscience, Inc.$17.8M-19.1%

SCN

Scienture Holdings, Inc.$15.2M-41.3%

ASB

Aspire Biopharma Holdings, Inc.$9.4M-60.2%

By revenue growth

Johnson & Johnson+8.1%

Viatris+1.6%

AMP

Amphastar Pharmaceuticals-1.4%

Aquestive Therapeutics, Inc.-7.3%

By net margin

Johnson & Johnson21.48%-3.5pp

AMP

Amphastar Pharmaceuticals11.0%-8.4pp

Viatris-2.04%+24.4pp

Aquestive Therapeutics, Inc.-137.08%-37.1pp

Profile

Nutriband Inc. is a biotechnology company focused on developing a portfolio of transdermal pharmaceutical products, primarily utilizing its proprietary AVERSA abuse-deterrent technology. The company's core value proposition is the integration of taste and sensory aversive agents into transdermal patches to prevent the abuse, misuse, and accidental exposure of potent drugs like opioids and stimulants. Beyond its proprietary pipeline, the company provides contract manufacturing and research services through its specialized subsidiaries.

Competitive position

Nutriband is a pioneer in abuse-deterrent transdermal technology, developing what could be the first-ever FDA-approved abuse-deterrent fentanyl patch.

GeographiesUnited States, Ireland

Customer segmentsPharmaceutical Companies, Healthcare Providers, Consumer Health Brands

Business modelResearch and Development, Contract Manufacturing (CMO), Contract Research (CRO), IP Licensing

SuppliersRaw material suppliers, Active Pharmaceutical Ingredient (API) manufacturers, Specialized chemical providers

CustomersHospitals, Pharmacies, Wholesale drug distributors, Consumer health retailers

CountryUnited States of America

Listed2017

Employees3.0

CEOGareth Sheridan

SectorHealthcare

IndustryBiotechnology

Websitenutriband.com

FilingsSEC EDGAR

Questions, answered.

What is Nutriband's market cap?: Nutriband (NTRB) has a market capitalization of $35.9M and trades on NASDAQ.
Who are Nutriband's competitors?: Nutriband's key competitors include Johnson & Johnson, Mylan, Aquestive Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Nutriband partner with?: Nutriband's notable partners include Kindeva Drug Delivery, Brand Institute, Inc, Health Advances, and others.
What subsidiaries does Nutriband have?: Nutriband's subsidiaries include 4P Therapeutics, Pocono Pharmaceuticals Inc., Active Intelligence LLC, and others.
Where is Nutriband headquartered?: Nutriband is headquartered in United States of America and employs approximately 3 people. It has been publicly traded since 2017.